These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10501918)

  • 21. The properties of the secreted gamma-glutamyl hydrolases from H35 hepatoma cells.
    Wang Y; Nimec Z; Ryan TJ; Dias JA; Galivan J
    Biochim Biophys Acta; 1993 Aug; 1164(3):227-35. PubMed ID: 8343522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
    van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ
    Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
    Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D
    Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines.
    Bodmer N; Walters DK; Fuchs B
    Pediatr Blood Cancer; 2008 Apr; 50(4):905-8. PubMed ID: 17534933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism-based inhibitors of folylpoly-gamma-glutamate synthetase and gamma-glutamyl hydrolase: control of folylpoly-gamma-glutamate homeostasis as a drug target.
    Coward JK; McGuire JJ
    Vitam Horm; 2008; 79():347-73. PubMed ID: 18804701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glutamyl hydrolase. pharmacological role and enzymatic characterization.
    Galivan J; Ryan TJ; Chave K; Rhee M; Yao R; Yin D
    Pharmacol Ther; 2000 Mar; 85(3):207-15. PubMed ID: 10739875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514).
    Jones RJ; Twelves CJ
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):13-22. PubMed ID: 12113062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
    Rosowsky A; Galivan J; Beardsley GP; Bader H; O'Connor BM; Russello O; Moroson BA; DeYarman MT; Kerwar SS; Freisheim JH
    Cancer Res; 1992 Apr; 52(8):2148-55. PubMed ID: 1313737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.
    Tonkinson JL; Worzalla JF; Teng CH; Mendelsohn LG
    Cancer Res; 1999 Aug; 59(15):3671-6. PubMed ID: 10446980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed.
    Wang Y; Zhao R; Chattopadhyay S; Goldman ID
    Cancer Res; 2002 Nov; 62(22):6434-7. PubMed ID: 12438230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport.
    Smith PG; Marshman E; Newell DR; Curtin NJ
    Br J Cancer; 2000 Feb; 82(4):924-30. PubMed ID: 10732767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MTA, A Novel Multitargeted Antifolate: from preclinical to phase I and beyond. Proceedings of a meeting. Ixtapa, Mexico, March 13-15, 1998.
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):1-110. PubMed ID: 10610578
    [No Abstract]   [Full Text] [Related]  

  • 33. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antifolate resistance in a HeLa cell line associated with impaired transport independent of the reduced folate carrier.
    Zhao R; Chattopadhyay S; Hanscom M; Goldman ID
    Clin Cancer Res; 2004 Dec; 10(24):8735-42. PubMed ID: 15623659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents.
    Calvert H
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):3-10. PubMed ID: 10598549
    [No Abstract]   [Full Text] [Related]  

  • 36. Antifolate pseudo-resistance due to elevated levels of thymidine and hypoxanthine in a commercial serum preparation.
    Simon M; Blatter J; Granzow C
    Anticancer Res; 2007; 27(2):769-73. PubMed ID: 17465201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin-dependent suppression in glutamyl hydrolase activity and elevated cellular methotrexate polyglutamates.
    Galivan J; Rhee MS
    Biochem Pharmacol; 1995 Nov; 50(10):1659-63. PubMed ID: 7503769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced folate carrier independent internalization of PEGylated pemetrexed: a potential nanomedicinal approach for breast cancer therapy.
    Vandana M; Sahoo SK
    Mol Pharm; 2012 Oct; 9(10):2828-43. PubMed ID: 22894559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MTA, a novel multitargeted antifolate, from preclinical to phase I and beyond: summary and conclusions.
    Calvert H
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):105-8. PubMed ID: 10598564
    [No Abstract]   [Full Text] [Related]  

  • 40. Preliminary results of a phase I study with MTA (LY231514) in combination with cisplatin in patients with solid tumors.
    Thödtmann R; Depenbrock H; Blatter J; Johnson RD; van Oosterom A; Hanauske AR
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):89-93. PubMed ID: 10598561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.